Mersana gets green light to resume ADC trial, but new dosing may slow progress

Mersana Therapeutics Inc. (NASDAQ:MRSN) said it will resume a Phase I trial of antibody-drug conjugate XMT-1522 after FDA lifted a partial clinical hold on the trial. However, Mersana fell $3.24 (23%) to $11.14 on Sept. 17 seemingly in response

Read the full 395 word article

User Sign In